Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody

mAbs

Volumn 2, Issue 5, 2010, Pages 565-570

  Feng, Yang ^a   Xiao, Dong ^a,c   Zhu, Zhongyu ^a,b   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Medimmune ^*  (United States)

Author keywords

DR4; Lymphoma; Therapeutic antibody; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CONATUMUMAB; CS 1008; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOGLOBULIN G; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; RECOMBINANT DEATH RECEPTOR 4; TIGATUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL STRAIN ST486; CELL SURFACE; CLINICAL TRIAL; GROWTH INHIBITION; HUMAN; NONHUMAN; PROTEIN ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDE LIBRARY; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77958568029     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.12570     Document Type: Article

References (21)

1. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Disc 2008; 7:1001-12.
2. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76:959-62. (Pubitemid 24106376)
3. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mole Cell 1999; 4:563-71.
4. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118:1979-90.
5. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22:7414-30.
6. Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004; 24:1133-40.
7. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64:4900-5.
8. L and RIP. Oncogene 2004; 23:5415-25.
9. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7:1362-9.
10. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006; 55:76-84.
11. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564-7.
12. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 2009; 7:1835-44.
13. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92:1430-41.
14. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162:2597-605.
15. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-60.
16. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15:751-61.
17. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27:4413-21.
18. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008; 105:11317-22.
19. Zhu Z, Dimitrov DS. Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mole Biol 2009; 525:129-42.
20. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mole Cancer Ther 2006; 5:114-20.
21. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-7.